Opna Bio’s Post

📄Download our latest case study presenting a preclinical platform for drug testing, consisting of organotypic mini-tumors combined with high content imaging screening (HCI) to discriminate different cell types and assess morphological, cytostatic and cytotoxic effects of drugs simultaneously. Download this case study to discover: ➡️A novel high content imaging platform to test drugs within the context of a reconstituted TME. ➡️A versatile platform capable of including tumor organoids of interest, fibroblasts and immune cells e.g. T cells, Monocytes, M1 and M2 macrophages. ➡️How fibroblasts represent the myofibroblast subpopulation, support tumor growth and confer SoC drug resistance Download now https://hubs.ly/Q02KMk6j0 #Oncology #Organoids

A novel covalent YAP/TAZ-TEAD inhibitor, SWTX-143, that binds to the palmitoylation pocket of all four TEAD isoforms. SWTX-143 caused irreversible and specific inhibition of the transcriptional activity of YAP/TAZ-TEAD in Hippo-mutant tumor cell lines. More importantly, YAP/TAZ-TEAD inhibitor treatment caused strong mesothelioma regression in subcutaneous xenograft models with human cells and in an orthotopic mesothelioma mouse model

What are the current and emerging states of biomarker testing in gastric cancer? In this molecular tumor board the presenters will discuss two cases of advanced gastric cancer with contrasting molecular features. They will review current and emerging predictive biomarkers of HER2, PD-L1 and CLDN18.2 to guide therapy selection in gastric cancer. They will also share best practices for tissue acquisition, processing, and handling to maximize the likelihood of successful genomic testing in oncology. #PrecisionOncology

(7/9) About 28,000 people in the U.S. are diagnosed each year with NRAS-mutant solid tumors, including #melanoma, #NSCLC and #CRC. Existing treatments either target all RAS proteins (pan-RAS), or target other downstream parts of the pathway, which leads to significant off-target toxicity and limits efficacy. We have created the first NRAS-selective inhibitor, which has been designed to address the liabilities of current pan-RAS inhibitors by only binding to NRAS. We expect to initiate clinical development of this inhibitor in the second half of 2025.

Glioblastoma stands as one of the most formidable challenges in solid tumor therapeutics, with current CAR-T approaches encountering limitations in achieving significant efficacy. However, the potential lies in harnessing T cells' tissue traversal capabilities and engineering them to penetrate the blood-brain barrier (BBB). This advancement could represent a transformative breakthrough, particularly for glioblastoma patients, offering a promising avenue for enhanced treatment strategies. https://lnkd.in/gz2tsMSt

What are the current and emerging states of biomarker testing in gastric cancer? In this molecular tumor board the presenters will discuss two cases of advanced gastric cancer with contrasting molecular features. They will review current and emerging predictive biomarkers of HER2, PD-L1 and CLDN18.2 to guide therapy selection in gastric cancer. They will also share best practices for tissue acquisition, processing, and handling to maximize the likelihood of successful genomic testing in oncology. #PrecisionOncology

What are the current and emerging states of biomarker testing in gastric cancer? In this molecular tumor board the presenters will discuss two cases of advanced gastric cancer with contrasting molecular features. They will review current and emerging predictive biomarkers of HER2, PD-L1 and CLDN18.2 to guide therapy selection in gastric cancer. They will also share best practices for tissue acquisition, processing, and handling to maximize the likelihood of successful genomic testing in oncology. #PrecisionOncology

What are the current and emerging states of biomarker testing in gastric cancer? In this molecular tumor board the presenters will discuss two cases of advanced gastric cancer with contrasting molecular features. They will review current and emerging predictive biomarkers of HER2, PD-L1 and CLDN18.2 to guide therapy selection in gastric cancer. They will also share best practices for tissue acquisition, processing, and handling to maximize the likelihood of successful genomic testing in oncology. #PrecisionOncology

What are the current and emerging states of biomarker testing in gastric cancer? In this molecular tumor board the presenters will discuss two cases of advanced gastric cancer with contrasting molecular features. They will review current and emerging predictive biomarkers of HER2, PD-L1 and CLDN18.2 to guide therapy selection in gastric cancer. They will also share best practices for tissue acquisition, processing, and handling to maximize the likelihood of successful genomic testing in oncology. #PrecisionOncology

What are the current and emerging states of biomarker testing in gastric cancer? In this molecular tumor board the presenters will discuss two cases of advanced gastric cancer with contrasting molecular features. They will review current and emerging predictive biomarkers of HER2, PD-L1 and CLDN18.2 to guide therapy selection in gastric cancer. They will also share best practices for tissue acquisition, processing, and handling to maximize the likelihood of successful genomic testing in oncology. #PrecisionOncology